Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Fred Hutchinson Cancer Center
With
This is a dose-escalation study of rivogenlecleucel. Each subject may receive up to 3 doses of rivogenlecleucel intravenously (IV), at intervals of no less than 28 days. Subjects meeting protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia, or encephalopathy will be treated with rimiducid infusion(s). After completion of study treatment, patients are followed up every 6 months for 5 years and then annually for 10 years.
Age
1–any
Sex
ALL
Healthy volunteers
Not accepted